<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2358</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">10.7324/IJCRR.2017.9216</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Genotypes and Markers of Hepatitis B and Antibodies to Hepatitis C virus in Patients with Chronic Liver Disease in a Tertiary Care Hospital in Puducherry&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Princess</surname><given-names>Isabella</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shashikala</surname><given-names/></name></contrib><contrib contrib-type="author"><name><surname>Ratnam</surname><given-names>Vivian Joseph</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alexander</surname><given-names>Thomas</given-names></name></contrib><contrib contrib-type="author"><name><surname>K.</surname><given-names>Prashanth</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kanungo</surname><given-names>Reba</given-names></name></contrib></contrib-group><volume>)</volume><issue/><fpage>40</fpage><lpage>44</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Background: Chronic liver disease leading to cirrhosis, hepatocellular carcinoma or hepatic failure have been associated with Hepatitis B and C virus infections. Detection of various viral markers of Hepatitis B have been reported to be useful tools to assess the progression of disease. In view of chronic liver disease being high in this population, an attempt was made to detect Hepatitis B viral markers and antibodies to Hepatitis C in patients reporting to this hospital.&#13;
&#13;
Methods: Serum samples from a cross section of hundred clinically confirmed cases of chronic liver disease were screened for HBsAg, total anti-HBc, total anti-HBs and HCV Ab. The patients who were positive for HBsAg were further screened for HBeAg, total anti HBe and IgM anti-HBc. Genotyping of Hepatitis B virus was done by nested PCR.&#13;
&#13;
Results: HBsAg positive patients accounted for 10% of the patients admitted to this hospital. HCV antibodies were also seen in 10% of the patients. A single patient tested positive for both HBsAg and HCV antibodies. Anti HBs was present in 11%, total anti HBc was detected in 42% and 87.5% had anti HBe. Two patients had IgM to HBc. Genotype C was detected in all nine HBV DNA positive samples.&#13;
&#13;
&#13;
Conclusion: Hepatitis B and C markers may be used to detect recent infection, active replication and carriers among cases of chronic liver disease. Genotype C is associated with faster progression to hepatocellular carcinoma, hence there is a need to monitor these patients.&#13;
</p></abstract><kwd-group><kwd>Hepatitis B</kwd><kwd> Hepatitis B markers</kwd><kwd> Chronic liver disease</kwd><kwd> HBV genotypes</kwd></kwd-group></article-meta></front></article>
